DTX 101

Drug Profile

DTX 101

Alternative Names: AAVrh10FIX; DTX101; Wild-type FIX AAVrh10 vector

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Dimension Therapeutics
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haemophilia B

Most Recent Events

  • 31 Jan 2017 Preliminary top-line efficacy and adverse events data from a phase I/II trial in Haemophilia B released by Dimension Therapeutics
  • 01 Jan 2017 Dimension Therapeutics initiates a long-term safety phase I/II trial for Haemophilia B in USA (NCT02971969)
  • 28 Nov 2016 Dimension Therapeutics plans a long-term safety phase I/II trial for Haemophilia B in USA (NCT02971969)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top